top of page

Clinical Trials Information System Reaches Major Milestone

EMA’s Management Board confirmed that the clinical trial EU Portal and Database, one of the main deliverables of the Clinical Trial Regulation and the key component of the Clinical Trial Information System (CTIS), is now fully functional and on track to go live by 31 January 2022. The Board confirmed that it has verified that the system meets the agreed requirements during an extraordinary meeting held on 21 April following an independent audit of this new IT system.

“The findings from the audit have reassured the Management Board that the EU Portal and Database now meet the functional specifications drawn up by EMA in collaboration with the European Commission and the Member States. We are all prepared to start working with the system,” said Christa Wirthumer-Hoche, chair of EMA’s Management Board. “The implementation of the Clinical Trial Regulation and CTIS will increase efficiency in the registration, conduct and supervision of clinical trials in the EU, particularly those taking place in multiple Member States, while ensuring utmost transparency for the public. This is one of the most complex and ambitious IT developments carried out by EMA and we look forward to its go-live in early 2022.”.

As a next step, the Board will inform the European Commission of this outcome. Once satisfied that the conditions set by the Clinical Trial Regulation have been met, the European Commission will publish a notice in the Official Journal of the European Union and six months after this publication, the Clinical Trial Regulation will start to apply and CTIS will go live. It is the desire of the Board, EMA and European Commission that the system goes live on 31 January 2022, which would imply that the Commission notice in the Official Journal would be published on 31 July 2021.

This Clinical Trial Regulation aims to harmonise the registration and supervision processes for clinical trials throughout the EU. CTIS will streamline these processes, ensuring the EU remains an attractive location for investment into clinical research.

CTIS will facilitate recruitment of trial participants by allowing sponsors and researchers to easily expand trials to other EEA countries, and will allow sponsors, researchers and national competent authorities to collaborate across borders for better results and knowledge-sharing.

The system will contain a public website with detailed information on and outcomes of all clinical trials conducted in the EU throughout their lifecycle, thus improving transparency and access to information for patients, healthcare workers and other interested parties.

The authorisation and oversight of clinical trials is the responsibility of Member States, however EMA manages CTIS. To prepare for the go-live of CTIS, training programmes for user groups have been initiated or are planned and extensive training materials have been made available on the EMA website. Commission guidance documents related to the implementation of the Clinical Trial Regulation can be found in EudraLex volume 10.

As ECOPNET, we strongly advise our partners to follow up the new developments on the clinical trials. When it will go live, CTIS will be the single EU entry point for clinical trial applications. Also, clinical trial sponsors will be able to apply for a clinical trial in all countries of the European Economic Area (EEA) with one application.

Source: European Medicines Agency Press Release


bottom of page